

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 May 2020 (22.05.2020)



(10) International Publication Number
WO 2020/102505 A1

(51) International Patent Classification:
C12N 7/06 (2006.01) A61L 2/00 (2006.01)

(21) International Application Number:
PCT/US2019/061436

(22) International Filing Date:
14 November 2019 (14.11.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/767,652 15 November 2018 (15.11.2018) US

(71) Applicant: BAYER HEALTHCARE LLC [US/US]; 100
Bayer Boulevard, Whippany, New Jersey 07981 (US).

(72) Inventors: LEE, Janice Hsiu Mei; 1030 Martin Luther
King Drive, Hayward, California 94541 (US). LIU,
Shengjiang; 8 Quail Run, Lafayette, California 95459 (US).
ZOU, June; 69 Sandpoint Drive, Richmond, California
94804 (US).

(74) Agent: JOYCE, Timothy et al.; Bayer HealthCare LLC,
Indianola, Pennsylvania 15051 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: VIRAL INACTIVATION METHODS FOR CONTINUOUS MANUFACTURING OF ANTIBODIES

(57) Abstract: This disclosure relates to methods for use in inactivating viruses. The virus inactivation methods are for use in continuous process manufacturing of a biologic such as an antibody, and include separating an eluate using a column, subjecting said eluate to an orthogonal treatment of low pH and detergent simultaneously wherein, the time for viral inactivation is reduced. In addition, the detergent can be added to buffer system in purification process to achieve the same effect. The biologic in each treatment case is retained.



WO 2020/102505 A1